48
Participants
Start Date
August 16, 2018
Primary Completion Date
June 3, 2019
Study Completion Date
June 3, 2019
R - Low dose of BI 655130
Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the periumbilical region following an overnight fast of at least 10 hours.
T1 - Low dose of BI 655130
Single low dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 1 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
T2 - Low dose of BI 655130
Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the thigh region following an overnight fast of at least 10 hours.
T3 - High dose of BI 655130
Single high dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 2 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
SGS Life Science Services - Clinical Research, Edegem
Lead Sponsor
Boehringer Ingelheim
INDUSTRY